Cancer remains the second-leading cause of death in the United States. This year, an estimated 1.7 million new cases will be diagnosed, with nearly...
News
Newsletter: October 2018
Greetings. Spring is in the air and the end of the year is fast approaching. Save the Date The final patient seminar and end of year function...
FDA Approves NGS-Based Test for Patients With ALL or MM
The U.S. Food and Drug Administration (FDA) has authorized the next-generation sequencing (NGS)–based clonoSEQ assay for the measurement of minimal...
Bisphosphonates for Patients Diagnosed With Multiple Myeloma
Clinical Question Among patients with multiple myeloma, is bisphosphonate therapy associated with lower rates of mortality, vertebral fractures,...
Adding Carfilzomib to Lenalidomide and Dexamethasone Extends Overall Survival in Multiple Myeloma
Compared with standard therapy of lenalidomide and dexamethasone, the addition of carfilzomib improved survival, without increasing the risk of...
Update on diagnosis, risk‐stratification and management
Multiple myeloma accounts for approximately 10% of hematologic malignancies. The diagnosis requires ≥10% clonal bone marrow plasma cells or a biopsy...
Trial represents ‘bold move’ for treatment of newly diagnosed myeloma
Researchers at The University of Alabama at Birmingham are recruiting for a phase 2 clinical trial designed to offer an innovative treatment...
Patient Seminar: From 45 South – The Otago Myeloma Research Trust
Presented by Dr Ian Morison on 1 August, 2018 Watch the video below
Access to prescription drug coverage improves myeloma survival
Patients with myeloma with outpatient prescription drug coverage were more likely to receive oral targeted agents instead of parenteral...
Clarithromycin Plus Bortezomib May Be Ineffective, Toxic in Multiple Myeloma
Clarithromycin plus bortezomib does not confer any additional efficacy and is a toxic combination among patients with multiple myeloma (MM),...
Leukogene Therapeutics receives funding to develop compound for resistant multiple myeloma
A $2 million phase 2 Small Business Technology Transfer (STTR) grant to optimize a promising new compound that has shown efficacy in preclinical...
UK panel rejects CAR T-cell therapy due to cost
An independent body that offers guidance to improve health and social care in England recommended against the use of axicabtagene ciloleucel, one of...